Stockscreener 앱 받기
2.10
0.00%
0.00
시간 외 거래:
2.11
0.010
+0.48%
Tuhura Biosciences Inc 주식(HURA)의 최신 뉴스
TuHURA Biosciences Draws Additional Funds From Credit Facility - TipRanks
Citizens reiterates TuHURA Biosciences stock rating on AML therapy progress - Investing.com India
TuHURA Biosciences Inc (NASDAQ: HURA) Share Price, HURA Stock News, HURA Share Price & Updates - kalkine.com.au
TuHURA Biosciences Expands Use of Revolving Credit Facility - TipRanks
TuHURA Biosciences Adopts 2026 Inducement Equity Plan - TipRanks
TuHURA receives FDA clearance for leukemia drug trial - Investing.com
TuHURA Biosciences Receives FDA Clearance for TBS-2025 - intellectia.ai
A cancer drug company CEO will speak in New York on Sept. 14 - Stock Titan
TuHURA Biosciences (HURA) Slips 0.93% as Stock Tests Key Technical LevelsNAAIM Leverage - dars.gov.et
TuHURA Biosciences to Present at Investment Conference - Intellectia AI
TuHURA Biosciences draws additional funds from credit facility - TipRanks
TuHURA Biosciences, Inc.Common Stock (HURA) Stock Price, News, Quote & History - FinancialContent
TuHURA (HURA) Q2 2026 Earnings: Reported EPS Tops Expectations; After Earnings: Shares Finish 5.12% Lower in the Available RecordQuarterly Earnings Report - dars.gov.et
TuHURA Biosciences | 8-K: Current report - Moomoo
H.C. Wainwright Maintains TuHURA Biosciences(HURA.US) With Buy Rating, Maintains Target Price $10 - Moomoo
Form 8K TuHURA Biosciences Inc For: 19 August By Investing.com - Investing.com South Africa
TuHURA (HURA) Technicals: Closes 5.56% Higher at $2.28 in the Latest Session; Boundary Watch: the Supplied Trading Band Runs From $2.17 to $2.39Breakout Confirmation - dars.gov.et
TuHURA Biosciences stockholders approve share issuance, elect directors at annual meeting - Investing.com Canada
HURA: All proposals passed, including director elections and share issuance, with no stockholder questions - TradingView
HURA: All proposals, including director elections and share issuance, were approved without dissent - TradingView
Citizens reiterates TuHURA Biosciences stock rating on pipeline progress By Investing.com - Investing.com South Africa
HURA Q2 2026 Earnings: Narrower Loss Beats Estimates, Shares Jump 7.4%Low Estimate Range - vinanet.vn
TuHURA Biosciences Expect Preliminary Results From IR Study IFX-2.0 With Keytruda for Deep Seated MCC in 1H2027 >HURA - Moomoo
TuHURA Biosciences Extends Runway as Immuno-Oncology Pipeline Advances - TipRanks
TuHURA Biosciences (NASDAQ:HURA) Posts Earnings Results, Beats Estimates By $0.01 EPS - MarketBeat
TuHURA Biosciences Highlights Phase III IFx Push, AML Trial Plans at Canaccord - MarketBeat
TuHURA Biosciences Q2 Results: EPS beats estimate, losses narrow 33% YoY - scanx.trade
TuHURA Secures $50M Credit Facility Extending Cash Runway into 2028 - Minichart
Tuhura Biosciences Reports Second Quarter 2026 Financial Results And Provides A Corporate Update - TradingView
Form 8K TuHURA Biosciences Inc For: 14 August By Investing.com - Investing.com Nigeria
TuHURA Biosciences (HURA) deepens R&D spend and adds $50M credit facility - Stock Titan
TuHURA Reports $1.0 Million Cash and Advances TBS-2025 AML Program - Quiver Quantitative
TuHURA Bios reports Q2 2026: $1.0M cash, R&D $6.6M, $50M credit facility extends runway - TradingView
TuHURA Biosciences Reports Second Quarter 2026 Financial Results and Provides a Corporate Update - PR Newswire
TuHURA Biosciences (HURA) Earnings Date and Reports 2026 - marketbeat.com
TuHURA at canaccord growth conference: late-stage push gains traction By Investing.com - Investing.com Nigeria
TuHURA at canaccord growth conference: late-stage push gains traction - Investing.com
Enterprise value to EBIT forward of TuHURA Biosciences, Inc. – NASDAQ:HURA - TradingView
HURA Q2'26 Earnings: revenue estimate is 0 USD - TradingView
TuHURA Biosciences (HURA) Expected to Release Quarterly Earnings on Thursday - MarketBeat
TuHURA Biosciences (HURA) Slips 1.38% as Biotech Stock Holds Above Key $2.03 SupportMax Pain Level - careplusvn.com
HURA Q1 2026 Earnings: EPS Miss Widens as Pre-Revenue Oncology Pipeline Drives CostsNew Analyst Coverage - vinanet.vn
HURA Q1 2026 Earnings: EPS Miss With No Revenue and Stock Advance Defies ResultsEarnings Season Review - careplusvn.com
TuHURA Biosciences Expands Revolving Credit Facility Utilization - TipRanks
TuHURA Biosciences Inc (HURA) Cash Flow - TradingKey
3.06%
2.55%
자본화:
|
볼륨(24시간):